Hoth Capex To Depreciation from 2010 to 2024

HOTH Stock  USD 0.83  0.01  1.22%   
Hoth Therapeutics' Capex To Depreciation is decreasing with slightly volatile movements from year to year. Capex To Depreciation is predicted to flatten to 175.40. Capex To Depreciation is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. View All Fundamentals
 
Capex To Depreciation  
First Reported
2010-12-31
Previous Quarter
184.64
Current Value
175.4
Quarterly Volatility
761.18809264
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Hoth Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hoth Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 742, Interest Expense of 368.8 K or Selling General Administrative of 4.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.53. Hoth financial statements analysis is a perfect complement when working with Hoth Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Hoth Therapeutics Correlation against competitors.
For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.

Latest Hoth Therapeutics' Capex To Depreciation Growth Pattern

Below is the plot of the Capex To Depreciation of Hoth Therapeutics over the last few years. It is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. Hoth Therapeutics' Capex To Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Hoth Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Capex To Depreciation10 Years Trend
Slightly volatile
   Capex To Depreciation   
       Timeline  

Hoth Capex To Depreciation Regression Statistics

Arithmetic Mean927.96
Geometric Mean506.79
Coefficient Of Variation82.03
Mean Deviation733.19
Median1,615
Standard Deviation761.19
Sample Variance579,407
Range1.5K
R-Value(0.85)
Mean Square Error168,137
R-Squared0.73
Significance0.000049
Slope(145.48)
Total Sum of Squares8.1M

Hoth Capex To Depreciation History

2024 175.4
2023 184.64
2020 160.55
2018 77.55

About Hoth Therapeutics Financial Statements

Investors use fundamental indicators, such as Hoth Therapeutics' Capex To Depreciation, to determine how well the company is positioned to perform in the future. Although Hoth Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Capex To Depreciation 184.64  175.40 

Currently Active Assets on Macroaxis

When determining whether Hoth Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hoth Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hoth Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hoth Therapeutics Stock:
Check out the analysis of Hoth Therapeutics Correlation against competitors.
For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.27)
Return On Assets
(0.46)
Return On Equity
(0.83)
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.